The Molecular Basis of Dual Agonism: How Tirzepatide Achieves Balanced GIPR/GLP-1R Activation

 

Tirzepatide, the first approved GIP/GLP-1 dual receptor agonist, does not achieve its effects through simple "balanced activation". Instead, it employs a precisely engineered, biased, imbalanced pharmacological strategy. This unique mechanism of action underlies its clinical superiority over selective GLP-1 receptor agonists in both glucose lowering and weight reduction.

Molecular Structure and Pharmacokinetic Foundation

Tirzepatide is a 39-amino-acid linear peptide built on a modified natural GIP sequence, with a C20 fatty diacid moiety conjugated via a linker to the lysine residue at position 20. This change to the fatty acid allows albumin to bind, which increases the half-life to about five days and makes it possible to take the drug once a week. From a pharmacokinetic perspective, this peptide design prolongs action and produces smoother drug exposure, reducing peak-concentration-related gastrointestinal adverse effects.

The "Imbalanced" Nature of Receptor Occupancy

Unlike the "balanced dual agonism" pursued in earlier theoretical frameworks, tirzepatide's actual pharmacological profile is imbalanced. Willard and colleagues calculated receptor occupancy at clinically effective doses and revealed a key finding: Tirzepatide occupies GIP receptors at substantially higher levels than GLP-1 receptors. This "GIPR-preferential" occupancy pattern echoes the natural physiological state, in which postprandial GIP plasma levels are three to five times higher than those of GLP-1.

Early animal studies proposed the concept of "balanced dual agonism", suggesting that simultaneous activation of both receptors could produce synergistic weight loss. However, subsequent clinical data indicate that tirzepatide's GIPR-preferential occupancy may be a critical source of its superior efficacy. In rodents, GIPR agonism is essential for dual agonists to enhance weight loss, and GIPR expression in the central nervous system is necessary for this effect.

Biased Signalling at the GLP-1 Receptor

Tirzepatide's behaviour at the GLP-1 receptor differs fundamentally from that of native GLP-1. Signalling studies demonstrate that tirzepatide biases toward cAMP generation at GLP-1R while markedly reducing β-arrestin recruitment. This bias directly results in weaker GLP-1R internalisation.

This bias has important functional consequences. In islet experiments, β-arrestin1 was shown to limit GLP-1-induced insulin secretory responses but had no effect on GIP or tirzepatide responses. This means tirzepatide enhances the persistence and magnitude of insulin secretion by circumventing β-arrestin-mediated negative regulation.

Structural Basis and Activation Mechanism

Cryo-electron microscopy structures provide atomic-level insight into tirzepatide's receptor activation mechanism. When tirzepatide binds GLP-1R, the receptor's extracellular domain transitions from a closed conformation in the inactive state to an open state. Extracellular loop 1 (ECL1) undergoes a displacement of approximately 7 Å, with residue W187 reorienting; the terminus of transmembrane helix 6 (TM6) exhibits greater unwinding, forming a helical break and sharp kink—hallmark features of G protein-coupled receptor activation.

At GIPR, tirzepatide binding reshapes the ECL1 conformation into a state distinct from that seen with GIP binding. These structural differences may explain tirzepatide's distinct signaling outputs at the two receptors.

Clinical Implications and Integrated Effects

The molecular design logic of tirzepatide can be summarized as follows: GIPR agonism serves as the core driving force, while biased GLP-1R activation acts as an amplifying mechanism. The broad tissue distribution of GIPR—including pancreatic islet cells, adipose tissue, and multiple central nervous system regions—allows GIPR agonism to reach metabolic regulatory nodes that GLP-1R cannot effectively cover. Simultaneously, biased signaling at GLP-1R sustains cAMP-mediated insulin secretion without inducing receptor internalization.

This "asymmetric" dual agonist strategy does not pursue equal contribution from both receptors but instead achieves system-level optimization of metabolic control through differential modulation of signal quality and quantity at each receptor. Clinical data support this design philosophy: tirzepatide outperforms selective GLP-1 receptor agonists in both HbA1c reduction and weight loss, with the efficacy advantage becoming more pronounced over longer treatment durations.

The success of tirzepatide reveals a core principle of multi-target drug design: the key to effectiveness may not lie in "balance" of action, but in "adaptation" of the action mode—customizing differentiated activation strategies based on each target receptor's physiological function and signaling characteristics. This understanding provides an important molecular design framework for the next generation of multi-receptor agonists.